Bio-Rad Laboratories Earnings: Here’s Why Shares are Down Now

Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.14%.

Bio-Rad Laboratories, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 20.67% to $1.65 in the quarter versus EPS of $2.08 in the year-earlier quarter.

Revenue: Rose 4.28% to $573.8 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Bio-Rad Laboratories, Inc. reported adjusted EPS income of $1.65 per share. By that measure, the company beat the mean analyst estimate of $1.34. It beat the average revenue estimate of $558.68 million.

Quoting Management: “We are pleased with our performance in the fourth quarter, with good momentum across many of our product areas,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “As we had expected, full-year results reflect macroeconomic challenges, which impacted many of our markets. Looking ahead to 2013, we anticipate a similar economic environment.”

Key Stats (on next page)…